Headquartered in Ingelheim.

Since it was established in 1885, the family business of researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary health has been committed.. Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees.

In a policy paper in PLoS Medicine, Raffaele Bugiardini and colleagues discuss the results of research, treat as best for patients with chest pain and normal angiograms. – Citation: Bugiardini R, Badimon L, Collins P, Erbel R, Angina, ‘normal’coronary and vascular dysfunction: risk assessment strategies. PLoS Med 4 : e12.. This press release is not for distribution in the U.S. Determines Related Links:Heinrich Wieland Prize Swiss Federal Institute of Technology ,normal-looking treat patients with chest pain have normal coronary arteries Who? A series of patients with chest pain are examined for coronary heart disease, but are found to have ‘normal-looking ‘coronary arteries.Source: Dainippon Sumitomo Pharma America.. Efficacy of once daily for Lurasidone has in four six-week, placebo-controlled trials detected with patients hospitalized with schizophrenia. The overall PEARL 1 and PEARL 2 clinical trials consisted . Clinical studies have demonstrated that Lurasidone generally well with limited weight increase or modifications in metabolic parameters tolerate. In addition Lurasidone been variations changes in the motor disorder parameters and prolactin. ‘provide Lurasidone may physicians a new, once-daily treatment for schizophrenia where many of unmet needs stay,’said Antony Loebel, vice president of clinical develop, ‘We believe Lurasidone has the potential symptoms of schizophrenia, while limiting annoying side effects like weight gain and associated metabolic risks.

, filed in a New Drug Application the U.S. Food and Drug Administration . Lurasidone of, untypical an investigational medicinal product antipsychotic agent to treat schizophrenia Filed to the request of, December 2009 contains data from search over 40 clinical trials involving more over 2500 treated patients Lurasidone. – The NDA is an important milestone for our company how we accelerated to global clinical development of Lurasidone and achieves earlier than expected submission to the FDA, said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co.